This study combined evolocumab (a PCSK9 inhibitor) with nivolumab (a PD-1 inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] inhibitor) in patients with metastatic NSCLC. The gene discussed is PCSK9; the disease is non-small cell lung carcinoma.